Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Phase 3b ADHAND trial data show tralokinumab (Adbry) significantly improved hand eczema severity, work productivity, and daily activity in adults with 

 and moderate-to-severe hand involvement, with a matching-adjusted indirect comparison (MAIC) favoring tralokinumab over dupilumab (Dupixent) on deep response and activity impairment.

According to LEO Pharma, the 32-week ADHAND trial (NCT05958407) marks the first phase 3b study designed specifically for patients with AD and moderate-to-severe hand eczema, a population with limited evidence from dedicated randomized trials.

ADHAND trial design and primary efficacy at 32 weeks

ADHAND was a phase 3b, international, multicenter, randomized, 32-week, double-blind, placebo-controlled, parallel-group, adaptive trial followed by a 16-week open-label treatment period. The trial enrolled adults with moderate-to-severe atopic hand eczema, a Hand Eczema Symptom Diary (HESD) itch score of at least 4, and an inadequate response to topical prescription medications within the prior year were enrolled. No background topical therapy was permitted on the hands during the double-blind period.

A total of 235 participants were randomized 2:1 to tralokinumab 300 mg every 2 weeks (n=156) or placebo (n=79). The trial’s primary endpoint was met, with 40.0% of patients receiving tralokinumab achieving IGA-AHE 0/1 at Week 16 versus 10.6% with placebo (treatment difference 29.7%; 95% CI, 19.0-40.4; 

<.001). Investigators pointed out response rates continued to climb through week 32, with 57.9% (77/133) of patients who continued tralokinumab achieving IGA-AHE 0/1 at that timepoint (observed cases).

On the Hand Eczema Severity Index (HECSI), 41.7% achieved HECSI-90 with tralokinumab versus 10.9% with placebo at Week 16 (treatment difference 30.8%; 95% CI, 20.0-41.5; 

<.001). All key secondary HECSI thresholds (HECSI-50, HECSI-75) were also significantly greater for tralokinumab at Week 16, with further improvements through Week 32.

Work Productivity, Daily Activity, Safety, & the MAIC vs Dupilumab

Among the 111 tralokinumab-treated participants who were currently employed, Work Productivity Impairment reductions were observed as early as week 2, the earliest measured timepoint. Activity Impairment, assessed among all participants regardless of employment status, showed significant improvement with tralokinumab versus placebo over the 16-week double-blind period. DLQI scores improved by a mean of 60.9% from baseline with tralokinumab versus 21.0% with placebo at week 16 (

Safety during the double-blind period was consistent with tralokinumab's established profile. Adverse events occurred in 60.3% of tralokinumab-treated patients and 60.8% of placebo patients. Serious adverse events were infrequent (1.9% vs 1.3%), and the incidence of severe adverse events was lower with tralokinumab (1.3%) than placebo (3.8%).

In a separate anchored MAIC comparing tralokinumab with dupilumab, individual patient data from ADHAND were weighted to match age, sex, race, and baseline HECSI from the LIBERTY-AD-HAFT trial (NCT04417894). Tralokinumab significantly outperformed dupilumab on HECSI-90 at Week 16 (27.0% vs 9.5%; risk difference 17.5%; 95% CI, 0.8-34.2; 

= .040) and on reduction in Percent Routine Activity Impairment (risk difference 16.0%; 95% CI, 4.8-27.1; 

= .005). Other endpoints, including IGA 0/1, HECSI-75, HECSI percent reduction, and itch and pain measures, were numerically in favor of tralokinumab.

A separate narrative review presented at 

Revolutionizing Atopic Dermatitis (RAD) 2026 Conference

 encompassing 16 clinical and real-world studies confirmed tralokinumab produced early, deep, and sustained improvements in high-burden area involvement, including head/neck and hands, across adult and adolescent patients regardless of skin color or prior systemic therapy history.

Ehst B, Warren RB, Hong HCC, et al. Tralokinumab treatment in patients with atopic dermatitis and moderate-to-severe hand involvement: results from the 32-week phase 3b ADHAND trial. Presented at: Georg Rajka International Symposium on Atopic Dermatitis 2026; June 2026.

Armstrong A, Kircik L, Metelitsa A, et al. Tralokinumab versus dupilumab for the treatment of moderate to severe atopic dermatitis with hand involvement: a matching-adjusted indirect comparison. Presented at: Georg Rajka International Symposium on Atopic Dermatitis 2026; June 2026.

Chovatiya R, Bunick CG, Golant AK, et al. Tralokinumab in patients with moderate-to-severe atopic dermatitis with high-burden area involvement. Presented at: Georg Rajka International Symposium on Atopic Dermatitis 2026; June 2026.

Articles

Phase 3b ADHAND evaluated tralokinumab in adults with atopic dermatitis and moderate-to-severe hand eczema without background hand topicals, demonstrating robust clinician- and patient-reported improvements through 32 weeks. At Week 16, tralokinumab significantly increased IGA-AHE 0/1 and HECSI-90 responses versus placebo, with response rates continuing to rise by Week 32. Early gains were seen in work productivity and routine activity, alongside substantial DLQI improvement. Safety mirrored the established profile. An anchored MAIC suggested advantages over dupilumab for deep response and activity impairment.

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC

 offer insights into the effects of roflumilast cream (Zoryve) across the pediatric age spectrum of 

Leveraging data from INTEGUMENT-INFANT, an open-label safety and exploratory efficacy trial of roflumilast 0.05% cream in infants aged 3 to 24 months, and a phase 3 vehicle-controlled trial of roflumilast 0.15% cream in patients aged 6 years and older with mild-to-moderate atopic dermatitis, investigators demonstrate the consistency in benefit for even the youngest patients included.

INTEGUMENT-INFANT: safety-primary trial in infants 3-24 months

INTEGUMENT-INFANT enrolled 101 infants aged 3 to less than 24 months with mild-to-moderate atopic dermatitis and at least 3% body surface area involvement, most of whom had a prior inadequate response, intolerance, or contraindication to topical corticosteroids. Patients received roflumilast cream 0.05% once daily for 4 weeks and the primary endpoints were treatment-emergent adverse events and application-site tolerability.

Exploratory efficacy results included vIGA-AD treatment success, which is defined as score 0/1 with ≥2-point improvement, in 34.0% of patients at week 2 and 49.0% at Week 4. IGA-Scalp success was achieved in 58.3% at week 4. Additionally, EASI-75 was achieved in 67.5% at week 4.

On the Worst Scratch Intensity-NRS (WSI-NRS), caregiver-reported itch improvement was seen in 60.3% at week 2 and 86.3% at the last observation. Dynamic Pruritus Score-25 improvement was detectable from 10 minutes after the first application.

“These results support safe and efficacious use of roflumilast cream 0.05% in patients aged as young as 3 months, a population with substantial disease burden and limited evidence-based treatment options,” wrote Lawrence Eichenfeld, MD, and colleagues, in their conclusion. 

Roflumilast 0.15% cream in patients aged 6 and older: regional and clinical sign data

In a vehicle-controlled phase 3 trial of roflumilast cream 0.15% in patients aged 6 years and older with mild-to-moderate AD, the poster examined improvements across all 4 EASI body regions and all 4 EASI clinical signs at weeks 1, 2, and 4.

Among the 884 roflumilast-treated and 453 vehicle-treated patients, roflumilast 0.15% produced numerically greater improvement than vehicle in each of the 4 body regions and all 4 clinical signs from Week 1 through Week 4. Improvements were consistent regardless of affected body region, supporting broad-spectrum efficacy across the entire body surface.

Investigators noted 76.1% of patients had moderate disease (vIGA-AD 3) at baseline, with a mean EASI of approximately 13.5, and a mean BSA involvement of 10%. 

“These results support that roflumilast cream 0.15% provides rapid and consistent benefit across body regions affected by [atopic dermatitis], offering an advanced targeted topical therapy alternative to commonly used topical therapies,” wrote Alexandra Golant, MD, and fellow investigators, in their conclusion.

Eichenfield LF, et al. INTEGUMENT-INFANT: once-daily roflumilast cream 0.05% in infants aged 3 to 24 months with atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Grada A, et al. Roflumilast cream 0.15% provides improvement across eczema area and severity index body regions and clinical signs in patients aged ≥6 years with mild-to-moderate atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Once-daily topical roflumilast demonstrated favorable tolerability and early efficacy signals across pediatric atopic dermatitis populations, including infants. In a 3–24 month open-label study of 0.05% cream, nearly half achieved vIGA-AD success by week 4, with high EASI-75 rates and rapid caregiver-reported itch improvement detectable within minutes. A separate phase 3 trial in patients ≥6 years using 0.15% cream showed consistent numerical improvements versus vehicle across all EASI body regions and all clinical signs from week 1 through week 4.

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients

Pulmonary nurse practitioner at Prisma Health in Greenville, South Carolina, and president elect, Association of Pulmonary APPs (APAPP)

APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN

Alpha-1 antitrypsin deficiency (AATD) remains significantly underdiagnosed, in part because of persistent misconceptions about who is at risk — and advanced practice providers (APPs) working in pulmonary medicine are among the most important stakeholders in changing that.

Sarah Tomashefski, MSN, NP-C, Lead Outpatient Pulmonary Advanced Practice Provider at Prisma Health in Greenville, South Carolina, Clinical Assistant Professor in the School of Health Research at Clemson University, and President-Elect of the Association of Pulmonary Advanced Practice Providers (APAPP), gave a talk on AATD awareness and screening at the APAPP annual conference and sat down with 

to further discuss the unique advantages of APPs in AATD care.

Despite recommendations from major respiratory societies to screen all patients with chronic obstructive pulmonary disease (COPD) for AATD regardless of age, ethnicity, or smoking history, only an estimated 10–15% of affected individuals in the United States have received a diagnosis, and diagnostic delays of 5 to 8 years remain stubbornly persistent.

Her central message: the disease is more common than most providers realize, it continues to be missed with regularity, and APPs are well positioned to catch it.

"People think it's a disease that happens to young smokers with basilar predominant emphysema," Tomashefski said. "But there are people all over the spectrum who can have this disease, and it looks very similar to asthma or COPD, so people forget to screen for it."

The diagnostic delay, she noted, often stems from patients cycling through multiple specialists with nonspecific complaints — shortness of breath, cough — and receiving a working diagnosis of asthma or obstructive lung disease without a complete workup. Inadequate provider knowledge about AATD and inattention to screening guidelines in patients with fixed airflow obstruction have been identified as key drivers of this gap.

 Her position: any patient with unexplained obstructive lung disease should be screened for AATD, and this is not currently happening consistently.

APPs are a natural lever point for closing that gap, she explained, both in practices where they see new pulmonary consults and in follow-up models where they co-manage patients alongside physicians. In both settings, the responsibility falls to APPs to check whether AATD screening has been completed and, if not, to order it. 

"It's our responsibility as APPs to be reading through their medical history thoroughly, and if that test got missed for some reason, to make sure we encourage the patient to get it done," she said.

She also noted that patient awareness of AATD remains low: many patients she screens have no idea the condition could be contributing to their lung disease, underscoring that closing the diagnostic gap requires education at both the provider and patient level.

Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. 

Stoller JK, et al. Detecting alpha-1 antitrypsin deficiency: current state, impediments, opportunities, and future directions. 

 2025;22(1):23–34. doi:10.1513/AnnalsATS.202406-600FR

Videos

Sarah Tomashefski, MSN, says persistent myths about who gets AATD and a failure to screen patients with any obstructive lung disease are driving a diagnostic gap APPs are uniquely positioned to close.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

 has been reshaped over the past decade by biologic agents targeting type 2 inflammatory pathways, with approved options now spanning 4 mechanistic classes: anti-IgE (omalizumab), anti-IL-4/IL-13 (dupilumab), anti-IL-5 and anti-IL-5 receptor (mepolizumab, benralizumab, reslizumab, and depemokimab), and anti-thymic stromal lymphopoietin (tezepelumab).¹ 

Long-term extension studies across these drug classes have demonstrated sustained reductions in annualized exacerbation rates over 3 to 4 years of follow-up, with the ANANKE study of benralizumab additionally demonstrating a median improvement in pre-bronchodilator FEV1 of approximately 400 mL at 96 weeks — a magnitude that has focused attention on mucus plug resolution as a meaningful and potentially underappreciated mechanism of spirometric benefit.² 

Depemokimab (Exdensur; GSK), a long-acting anti-IL-5 monoclonal antibody dosed every 6 months, received FDA approval on December 16, 2025, based on SWIFT-1 and SWIFT-2, which demonstrated 58% and 48% reductions in annualized exacerbation rates, respectively — establishing twice-yearly dosing as a first for the anti-IL-5 class.³ Despite this expanding armamentarium, prescribing rates remain far below the scale of the eligible patient population, with data from Florida indicating that only approximately 1 in 10 patients with eosinophilic asthma on inhaled corticosteroids are currently receiving biologic therapy.

 convened a panel of pulmonologists from across South Florida for an in-depth roundtable discussion on advancing biologic therapy for asthma and chronic obstructive pulmonary disease (COPD) in a complex real-world prescribing environment. The forum was moderated by Trishul Siddharthan, MD, an associate professor at the University of Miami and director of clinical trials for severe asthma and COPD, and included clinicians representing Cleveland Clinic Treasure Coast and Orlando-area medical centers to discuss bridging clinical trial data with the insurance, administrative, and patient-engagement realities of South Florida practice, including a payer environment dominated by Medicaid Advantage plans for which many high-cost biologics remain subject to active prior authorization management.

The timing of the forum reflected a field at an inflection point in COPD management. Dupilumab received FDA approval for COPD in September 2024 based on BOREAS and NOTUS, which demonstrated approximately 30% and 34% reductions in moderate-to-severe exacerbation rates, respectively, in patients with blood eosinophil counts of 300 cells/µL or greater on maximal triple inhaled therapy — alongside early FEV1 improvements that were sustained through 52 weeks.⁴ Mepolizumab's GOLD-endorsed indication in COPD, supported by the METREX and METREO programs, expanded the biologic-eligible population to patients with eosinophil counts as low as 150 cells/µL when combined with a prior-year count above 300 cells/µL.⁵ 

Simultaneously, phase 3 data announced in March 2026 from AstraZeneca's OBERON and TITANIA trials showed that tozorakimab, an investigational IL-33 inhibitor, met its primary endpoint of reducing annualized moderate-to-severe exacerbations in a broad COPD population independent of eosinophil count or smoking status — a finding not yet published in full but representing the first IL-33–targeting biologic to achieve this endpoint in replicate confirmatory trials.⁶ 

The panel reached broad consensus that biologic selection in asthma is driven in practice by a combination of comorbidity profile, patient preference for injection frequency, and insurance coverage rather than by granular pharmacologic differentiation. Dupilumab was identified as the preferred first choice for patients with concurrent atopic dermatitis or eosinophilic esophagitis given its shared indication, while mepolizumab's once-monthly dosing was frequently cited as a patient preference advantage over dupilumab's biweekly regimen. Depemokimab was positioned as a niche agent appropriate for non-adherent patients and those with needle phobia, with panel reservations expressed regarding its use in women of reproductive age and the potential for symptom recurrence in the weeks preceding a repeat dose. 

The discussion of mucus plugging represented a notable clinical focal point: Siddharthan outlined VESTIGE and CASCADE data demonstrating that dupilumab and tezepelumab, respectively, reduce CT-quantified mucus plug burden within weeks of initiation — with corresponding early FEV1 improvement in patients with high baseline plug scores — an observation that may explain the disproportionate spirometric gains observed with benralizumab in ANANKE.²,⁷,⁸ Several panelists acknowledged manually reviewing CT scans for mucus plugs but noted the absence of standardized clinical scoring tools as a practical barrier, with AI-augmented fractional mucus volume platforms identified as a promising near-term solution. As one panelist noted: "There is software that's currently on the market that's AI augmented and that is actually not doing a segment by segment, but they give you a fractional mucus volume so you get a better idea of improvement."

The COPD biologic discussion surfaced both clinical enthusiasm and significant unresolved questions around prescribing access and evidence adequacy. The panel endorsed dupilumab and mepolizumab as meaningful tools for eosinophilic COPD, with panelists citing a 30% to 34% reduction in exacerbations as clinically significant given that post-hospitalization COPD mortality reaches approximately 31% within 2 years of a severe exacerbation.⁹ The distinction between emphysematous and bronchitic disease subtypes was identified as the primary driver of agent selection, with eosinophil counts between 150 and 300 cells/µL favoring mepolizumab and counts above 300 cells/µL supporting either agent. Inpatient biologic initiation programs at point of discharge — modeled on heart failure readmission-reduction protocols — were described as actively being implemented at one participating institution, with depemokimab cited as uniquely suited for this model given that a single administration confers 6 months of protection. 

The greatest unmet need identified was cost-effectiveness data: several panelists noted that dupilumab's rejection by England's National Institute for Health and Care Excellence (NICE) for COPD based on cost-effectiveness modeling stands as a cautionary example of how the absence of this evidence type translates directly into restricted access. Tozorakimab was identified with near-universal enthusiasm as the most anticipated next development, with OBERON and TITANIA data suggesting exacerbation reductions in a broad population that includes patients below the 150-cells/µL eosinophil threshold that currently limits available COPD biologics.⁶ Unmet needs highlighted for future research included early-intervention studies examining whether biologic treatment of asthma can prevent COPD, formal age-extension trials for depemokimab and tezepelumab in patients under 6 years, and cost-effectiveness analyses that would most likely shift payer behavior toward broader access.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2024. Accessed June 2026. 

https://ginasthma.org/2024-gina-report-global-strategy-for-asthma-management-and-prevention

Vultaggio A, Aliani M, Altieri E, et al. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96 weeks: data from the ANANKE study. 

 2023;24(1):135. doi:10.1186/s12931-023-02439-w

Jackson DJ, Wechsler ME, Jackson DJ, et al; SWIFT-1 and SWIFT-2 Investigators. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. 

 2024;391(24):2337–2349. doi:10.1056/NEJMoa2406673

Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. 

 2023;389(3):205–214. doi:10.1056/NEJMoa2303951

Pavord ID, Chanez P, Criner GJ, et al; METREX and METREO Investigators. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. 

 2017;377(17):1613–1629. doi:10.1056/NEJMoa1708208

AstraZeneca. Tozorakimab met primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD. Press release. March 27, 2026. Accessed June 2026. 

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html

Maspero J, Laidlaw TM, Onoue M, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. 

Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. 

 2023;2(10):EVIDoa2300135. doi:10.1056/EVIDoa2300135

Sethi S, Yin J, Anderson PK. Hospitalization for acute exacerbations of COPD and 2-year mortality: a systematic review and meta-analysis. 

 2017;122:1–8. doi:10.1016/j.rmed.2016.11.004

Type 2–targeted biologics now dominate severe asthma care across four mechanistic classes, with extension data supporting sustained exacerbation reduction and notable FEV1 gains potentially linked to mucus plug resolution. Twice-yearly depemokimab expands anti–IL-5 options but real-world utilization remains low amid prior authorization and adherence barriers. COPD management is entering a biologic era, with dupilumab and mepolizumab demonstrating clinically meaningful exacerbation reductions in eosinophilic phenotypes. IL-33 inhibition with tozorakimab may broaden eligibility beyond eosinophil thresholds, sharpening focus on access and cost-effectiveness.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

Individualizing Treatment Selection in Atopic Dermatitis, With Harrison Nguyen, MD, MBA, MPH

2026 Revolutionizing Atopic Dermatitis (RAD) Conference

 in Nashville, Harrison Nguyen, MD, MBA, MPH, spoke in an interview on the importance of individualized treatment selection in atopic dermatitis following his portion of a session at the meeting, highlighting ways in which clinicians should tailor therapy decisions to the unique needs of each patient.

 interview, Nguyen identified quality of life as the single most important factor influencing his decision to escalate treatment from topical therapies to systemic options. While disease severity remains an important consideration, he noted that the impact of atopic dermatitis on sleep, daily functioning, work, and school often provides the clearest indication that additional intervention may be necessary. He also pointed to the burden of topical therapy itself, particularly among caregivers of pediatric patients, as an important but sometimes overlooked factor when evaluating treatment needs.

“The burden of having to apply topicals can be really challenging for caregivers,” Nguyen said. “We really want to understand the patient's journey [and] impacts on quality of life. Then from there, we also go into things like preferences, comorbidities, and of course, manifestations of disease.”

Beyond quality-of-life considerations, Nguyen described selection of treatments as being increasingly guided by different patient-specific factors. The factors include comorbid conditions, the preferences of individuals, and the anatomic distribution of one’s atopic dermatitis. For example, involvement of regions such as the head and neck, hands, or feet may impact the therapeutic choices clinicians make and help them to determine which available options are most appropriate for a given individual.

Nguyen also pointed to the rapidly expanding therapeutic landscape as having changed his approach to disease management. Rather than following a rigid treatment sequence, he highlighted the value of “meeting patients where they are” in their disease journey. In practice, he noted, this can mean recognizing when a patient’s disease burden warrants systemic therapy from the outset rather than requiring them to progress through multiple topical treatments first.

While Nguyen noted biologics often function as his preferred first-line systemic agent, he also noted the growing role of Janus kinase (JAK) inhibitors for select patients who may see benefit from that mechanism of action. The expanding number of available therapies, he explained, has created new opportunities to personalize care rather than rely on a one-size-fits-all treatment approach.

Nguyen had no relevant financial disclosures of note.

Nguyen H, Bunick C, Cotter D, Shahriari M. Medical Crossfire and Clinical Case Challenge. Session presented at: 2026 Revolutionizing Atopic Dermatitis Conference; June 17-19, 2026; Nashville, TN.

Nguyen H. Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH. HCPLive. June 19, 2026. 

https://www.hcplive.com/view/emerging-evidence-atopic-dermatitis-management-harrison-nguyen-md-mba-mph

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH

David Rosmarin, MD, discussed STAT6 inhibitors, ITK inhibitors, bispecifics, hand eczema, and endpoints at the RAD 2026 Conference.

STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD

At SDPA 2026, Shanna Miranti, PA-C, outlined how dermatology PAs can sharpen diagnostic speed and accuracy through structured visual practice and algorithm-based thinking.

Strategic Alliance Partnership

How Dermatology PAs Can Master Rapid Diagnostic Recognition

Explore plasma exchange as a management strategy for FCS in pregnancy and the clinical red flags that should prompt referral to a lipid specialist.

Video Series

FCS in Pregnancy and Optimizing Specialist Referral for High-Risk Patients

Understand the evidence base for LPL-targeted treatment strategies in FCS, when to discontinue ineffective agents, and how to assess atherosclerosis risk in this population.

Managing FCS: LPL-Targeted Therapy, Drug Rationalization, and Atherosclerosis Risk

Explore how the North American FCS score enables clinical diagnosis when genetic testing is unavailable, and why gastroenterologists remain an undertapped referral source.

Diagnosing FCS Without Genetic Confirmation: Scoring Tools and Referral Gaps

Discover how heterozygous LPL variants, polygenic contributors, and multifactorial presentations complicate FCS classification and the implications for clinical recognition.

Beyond Classic LPL Deficiency: The Genetic Complexity of FCS

Understand how to systematically exclude secondary causes and identify FCS in patients presenting with severe hypertriglyceridemia and recurrent pancreatitis.

Evaluating Severe Hypertriglyceridemia: Differential Diagnosis and FCS Recognition

Diana Varghese, MD, is an internal medicine fellow at the University of Maryland.

Diana Varghese, MD, discusses her recent study noting a 9% prevalence of PA among patients with incident hypertension and providing targets for further screening strategies.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Primary Aldosteronism More Common Than Previously Believed, Requires Increased Screening

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Song emphasized that clinicians should think beyond the skin when managing patients with atopic dermatitis.

Latest News

RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC

Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients

APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN

Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD

Individualizing Treatment Selection in Atopic Dermatitis, With Harrison Nguyen, MD, MBA, MPH